{"id":"nimotuzumab-toripalimab-cisplatin-gemcitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (from toripalimab)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nimotuzumab blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Toripalimab is a PD-1 checkpoint inhibitor that releases immune suppression, allowing T cells to attack cancer cells. Cisplatin and gemcitabine are cytotoxic chemotherapy agents that directly damage tumor DNA. Together, this quadruple regimen combines targeted therapy, immunotherapy, and chemotherapy.","oneSentence":"This combination uses an EGFR-targeting monoclonal antibody (nimotuzumab) and a PD-1 inhibitor (toripalimab) alongside chemotherapy (cisplatin and gemcitabine) to block tumor growth signaling and enhance immune-mediated cancer cell killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:07.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic squamous cell carcinoma of the head and neck"},{"name":"Non-small cell lung cancer (NSCLC)"}]},"trialDetails":[{"nctId":"NCT06509009","phase":"PHASE2","title":"Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-30","conditions":"Nasopharyngeal Carcinoma by AJCC V8 Stage","enrollment":30},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06026878","phase":"PHASE3","title":"GNT Induction Treatment in Locally Advanced NPC","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2023-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine","genericName":"Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses an EGFR-targeting monoclonal antibody (nimotuzumab) and a PD-1 inhibitor (toripalimab) alongside chemotherapy (cisplatin and gemcitabine) to block tumor growth signaling and enhance immune-mediated cancer cell killing. Used for Locally advanced or metastatic squamous cell carcinoma of the head and neck, Non-small cell lung cancer (NSCLC).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}